{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:34:04Z","timestamp":1770510844568,"version":"3.49.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.mayocp.2012.02.022","type":"journal-article","created":{"date-parts":[[2012,7,2]],"date-time":"2012-07-02T04:19:54Z","timestamp":1341202794000},"page":"683-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Strategies to Reduce the Tampering and Subsequent Abuse of Long-acting Opioids: Potential Risks and Benefits of Formulations With Physical or Pharmacologic Deterrents to Tampering"],"prefix":"10.1016","volume":"87","author":[{"given":"Steven P.","family":"Stanos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Bruckenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Barkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.mayocp.2012.02.022_bib1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1532-5415.2009.02376.x","article-title":"Pharmacological management of persistent pain in older persons","volume":"57","year":"2009","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.mayocp.2012.02.022_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.joca.2007.12.013","article-title":"OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines","volume":"16","author":"Zhang","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"issue":"2","key":"10.1016\/j.mayocp.2012.02.022_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"J Pain"},{"issue":"9","key":"10.1016\/j.mayocp.2012.02.022_bib4","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1185\/030079906X132398","article-title":"Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain","volume":"22","author":"Bhamb","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.022_bib5","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1525-1497.2006.00412.x","article-title":"Primary care provider concerns about management of chronic pain in community clinic populations","volume":"21","author":"Upshur","year":"2006","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.mayocp.2012.02.022_bib8","unstructured":"Associated Press. FlA. Gov. Scott signs bill regulating 'pill mills'. http:\/\/wvgazette.com\/ap\/ApPolitics\/201106030993?page=1. Accessed June 12, 2012."},{"issue":"2","key":"10.1016\/j.mayocp.2012.02.022_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/J354v20n02_03","article-title":"Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation","volume":"20","author":"Passik","year":"2006","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.022_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11926-008-0003-z","article-title":"Abuse-deterrent opioid formulations: are they a pipe dream?","volume":"10","author":"Katz","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.mayocp.2012.02.022_bib12","series-title":"Guidance for Industry: Assessment of Abuse Potential of Drugs.","year":"2010"},{"key":"10.1016\/j.mayocp.2012.02.022_bib13","series-title":"Embeda\u00ae Full Prescribing Information","year":"2009"},{"key":"10.1016\/j.mayocp.2012.02.022_bib14","series-title":"Full Prescribing Information","year":"2010"},{"key":"10.1016\/j.mayocp.2012.02.022_bib15","series-title":"OXECTA\u00ae Full Prescribing Information","year":"2011"},{"issue":"2","key":"10.1016\/j.mayocp.2012.02.022_bib16","first-page":"423","article-title":"Medical malpractice and new devices: defining an elusive standard of care","volume":"19","author":"Greenberg","year":"2009","journal-title":"Health Matrix Clevel"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jpain.2007.11.014","article-title":"Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R)","volume":"9","author":"Butler","year":"2008","journal-title":"J Pain"},{"issue":"1-2","key":"10.1016\/j.mayocp.2012.02.022_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.pain.2007.01.014","article-title":"Development and validation of the Current Opioid Misuse Measure","volume":"130","author":"Butler","year":"2007","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.022_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1526-4637.2005.00072.x","article-title":"Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool","volume":"6","author":"Webster","year":"2005","journal-title":"Pain Med"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.022_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.36076\/ppj.2006\/9\/57","article-title":"Does adherence monitoring reduce controlled substance abuse in chronic pain patients?","volume":"9","author":"Manchikanti","year":"2006","journal-title":"Pain Physician"},{"issue":"2","key":"10.1016\/j.mayocp.2012.02.022_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1526-4637.2005.05031.x","article-title":"Universal precautions in pain medicine: a rational approach to the treatment of chronic pain","volume":"6","author":"Gourlay","year":"2005","journal-title":"Pain Med"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib22","first-page":"301","article-title":"Rational use and interpretation of urine drug testing in chronic opioid therapy","volume":"37","author":"Reisfield","year":"2007","journal-title":"Ann Clin Lab Sci"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3810\/pgm.2009.07.2035","article-title":"Urine toxicology testing in chronic pain management","volume":"121","author":"Cone","year":"2009","journal-title":"Postgrad Med"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.022_bib24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.5055\/jom.2007.0022","article-title":"Family physicians' proficiency in urine drug test interpretation","volume":"3","author":"Reisfield","year":"2007","journal-title":"J Opioid Manag"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.022_bib25","first-page":"6","article-title":"a consensus statement from the American Academy of Pain Medicine and the American Pain Society","volume":"13","year":"1997","journal-title":"Clin J Pain"},{"issue":"2, Suppl","key":"10.1016\/j.mayocp.2012.02.022_bib26","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.36076\/ppj.2008\/11\/S155","article-title":"Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility","volume":"11","author":"Manchikanti","year":"2008","journal-title":"Pain Physician"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.36076\/ppj.2003\/6\/425","article-title":"Screening for controlled substance abuse in interventional pain management settings: evaluation of an assessment tool","volume":"6","author":"Manchikanti","year":"2003","journal-title":"Pain Physician"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/15360288.2010.524979","article-title":"Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain","volume":"24","author":"Brushwood","year":"2010","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.mayocp.2012.02.022_bib29","article-title":"Update on formulations to deter tampering","author":"Sellers","year":"2011","journal-title":"College on Problems of Drug Dependence 73rd Annual Scientific Meeting"},{"issue":"12","key":"10.1016\/j.mayocp.2012.02.022_bib30","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.2105\/AJPH.2009.180646","article-title":"Age and gender trends in long-term opioid analgesic use for noncancer pain","volume":"100","author":"Campbell","year":"2010","journal-title":"Am J Public Health"},{"issue":"22","key":"10.1016\/j.mayocp.2012.02.022_bib31","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1001\/jama.2008.802","article-title":"Patterns of abuse among unintentional pharmaceutical overdose fatalities","volume":"300","author":"Hall","year":"2008","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jpainsymman.2005.09.001","article-title":"Drug crime is a source of abused pain medications in the United States","volume":"30","author":"Joranson","year":"2005","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib34","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/fampra\/cmm027","article-title":"Prevalence and comparative troublesomeness by age of musculoskeletal pain in different body locations","volume":"24","author":"Parsons","year":"2007","journal-title":"Fam Pract"},{"issue":"10","key":"10.1016\/j.mayocp.2012.02.022_bib35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jpain.2008.05.005","article-title":"Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders","volume":"9","author":"Tsang","year":"2008","journal-title":"J Pain"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.022_bib36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1526-4637.2009.00603.x","article-title":"Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment","volume":"10","author":"Inciardi","year":"2009","journal-title":"Pain Med"},{"issue":"10","key":"10.1016\/j.mayocp.2012.02.022_bib37","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2165\/11584260-000000000-00000","article-title":"Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?","volume":"24","author":"Schneider","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.mayocp.2012.02.022_bib38","article-title":"Alcohol does not compromise abuse-resistant CR oxycodone","author":"de Kater","year":"2008","journal-title":"Paper presented at: American Academy of Pain Medicine 24th Annual Meeting; February 12-16"},{"key":"10.1016\/j.mayocp.2012.02.022_bib39","article-title":"Abuse-resistant, controlled-release oxycodone treats chronic pain","author":"Merrigan","year":"2008","journal-title":"Paper presented at: American Academy of Pain Medicine 24th Annual Meeting; February 12-16"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.022_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1526-4637.2009.00737.x","article-title":"Estimating attractiveness for abuse of a not-yet-marketed \u201cabuse-deterrent\u201d prescription opioid formulation","volume":"11","author":"Butler","year":"2010","journal-title":"Pain Med"},{"key":"10.1016\/j.mayocp.2012.02.022_bib41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1477-7517-3-5","article-title":"Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers","volume":"3","author":"Butler","year":"2006","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.mayocp.2012.02.022_bib44","first-page":"455","article-title":"Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release","volume":"5","author":"Benedek","year":"2011","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.022_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpain.2011.10.011","article-title":"The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets","volume":"13","author":"Fiske","year":"2012","journal-title":"J Pain"},{"key":"10.1016\/j.mayocp.2012.02.022_bib46","article-title":"Oxymorphone extended release tablets with improved tamper resistant properties","author":"Galia","year":"2012","journal-title":"Paper presented at: American Pain Society 31st Annual Scientific Meeting; May 16-19"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.022_bib47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1590\/S1678-77572006000600011","article-title":"The influence of gender and bruxism on the human maximum bite force","volume":"14","author":"Calderon Pdos","year":"2006","journal-title":"J Appl Oral Sci"},{"key":"10.1016\/j.mayocp.2012.02.022_bib48","article-title":"Drug is harder to abuse, but users persevere","author":"Goodnough","year":"2011","journal-title":"New York Times"},{"issue":"9","key":"10.1016\/j.mayocp.2012.02.022_bib49","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1185\/03007990903120158","article-title":"Opioid switching and rotation in primary care: implementation and clinical utility","volume":"25","author":"Slatkin","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.mayocp.2012.02.022_bib50","article-title":"Daily average consumption analysis of low back pain and osteoarthritis patients using oxymorphone extended-release and oxycodone hydrochloride controlled-release tablets in a commercially insured population","author":"Berner","year":"2010","journal-title":"Paper presented at: International Society for Pharmacoeconomics and Outcomes Research 15th Annual International Meeting; May 15-19"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.022_bib51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.5055\/jom.2011.0061","article-title":"Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users","volume":"7","author":"Schoedel","year":"2011","journal-title":"J Opioid Manag"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib52","doi-asserted-by":"crossref","first-page":"E343","DOI":"10.36076\/ppj.2011\/14\/E343","article-title":"Pharmacology of opioids in the treatment of chronic pain syndromes","volume":"14","author":"Vallejo","year":"2011","journal-title":"Pain Physician"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.022_bib53","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2008.05.007","article-title":"The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers","volume":"98","author":"Walsh","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mayocp.2012.02.022_bib55","article-title":"Tamper-resistant properties of a novel, multiparticulate, extended-release formulation of oxycodone for the treatment of moderate to severe pain","author":"Fleming","year":"2010","journal-title":"Paper presented at: American Academy of Pain Medicine 26th Annual Meeting; February 3-6"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib56","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jpainsymman.2009.08.013","volume":"39","author":"Ridgway","year":"2010","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.022_bib57","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.pmrj.2010.03.011","article-title":"Strategies to optimize pain management with opioids while minimizing risk of abuse","volume":"2","author":"Brennan","year":"2010","journal-title":"PM R"},{"issue":"2","key":"10.1016\/j.mayocp.2012.02.022_bib60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/dta.220","article-title":"Adulterants in illicit drugs: a review of empirical evidence","volume":"3","author":"Cole","year":"2011","journal-title":"Drug Test Anal"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.022_bib62","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.nano.2010.06.006","article-title":"Antioxidant idebenone-loaded nanoparticles based on chitosan and N-carboxymethylchitosan","volume":"6","author":"Amorim Cde","year":"2010","journal-title":"Nanomed"},{"issue":"11","key":"10.1016\/j.mayocp.2012.02.022_bib63","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1592\/phco.26.11.1641","article-title":"Povidone-iodine-induced burn: case report and review of the literature","volume":"26","author":"Lowe","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"1-2","key":"10.1016\/j.mayocp.2012.02.022_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0378-5173(01)00930-9","article-title":"Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers","volume":"233","author":"Teshima","year":"2002","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib65","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1468-3083.2007.02477.x","article-title":"Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test","volume":"22","author":"Engel","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.mayocp.2012.02.022_bib66","unstructured":"Freeland D, Spivey R, Colucci R. Phase II study of the safety and tolerability of niacin combined with oxycodone HCl 5 mg vs. oxycodone HCl 5 mg alone in healthy adult subjects. Paper presented at: College on Problems of Drug Dependence 71st Annual Meeting; June 20-25, 2009; Reno\/Sparks, NV."},{"key":"10.1016\/j.mayocp.2012.02.022_bib67","article-title":"Phase II, randomized, double-blind study in fasted and fed healthy subjects to evaluate the dose-response for flushing, tolerability, and safety of escalating doses of niacin","author":"Wood","year":"2009","journal-title":"Paper presented at: College on Problems of Drug Dependence 71st Annual Meeting; June 20-25"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.022_bib68","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1185\/03007995.2010.548291","article-title":"Efficacy and safety of oxycodone HCl\/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery","volume":"27","author":"Daniels","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.022_bib69","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jpain.2005.01.356","article-title":"Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex","volume":"6","author":"Chindalore","year":"2005","journal-title":"J Pain"},{"issue":"12","key":"10.1016\/j.mayocp.2012.02.022_bib70","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jpain.2006.05.005","article-title":"Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain","volume":"7","author":"Webster","year":"2006","journal-title":"J Pain"},{"issue":"1-2","key":"10.1016\/j.mayocp.2012.02.022_bib71","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0376-8716(99)00074-5","article-title":"Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet","volume":"58","author":"Amass","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mayocp.2012.02.022_bib72","series-title":"Suboxone\u00ae Full Prescribing Information","year":"2010"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.022_bib73","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.annemergmed.2009.10.013","article-title":"Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda)","volume":"55","author":"Jang","year":"2010","journal-title":"Ann Emerg Med"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib74","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5055\/jom.2010.0028","article-title":"Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature","volume":"6","author":"Ruan","year":"2010","journal-title":"J Opioid Manag"},{"issue":"6","key":"10.1016\/j.mayocp.2012.02.022_bib77","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.clinthera.2010.05.011","volume":"32","author":"Johnson","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.mayocp.2012.02.022_bib78","article-title":"Bioavailability of ALO-01 and marketed extened-release morphine","author":"Stanton","year":"2009","journal-title":"Paper presented at: American Academy of Pain Medicine 25th Annual Meeting; January 27-31"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib79","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3810\/pgm.2010.07.2179","article-title":"Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain","volume":"122","author":"Katz","year":"2010","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.022_bib80","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5055\/jom.2008.0018","article-title":"Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review","volume":"4","author":"Sloan","year":"2008","journal-title":"J Opioid Manag"},{"key":"10.1016\/j.mayocp.2012.02.022_bib81","series-title":"Weiner's Pain Management: A Practical Guide for Clinicians","first-page":"789","article-title":"Opioids used in primary care for the management of pain: a pharmacologic, pharmacotherapeutic, and pharmacodynamic overview","author":"Barkin","year":"2006"},{"issue":"3","key":"10.1016\/j.mayocp.2012.02.022_bib82","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.tpj.6500362","article-title":"Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers","volume":"6","author":"Lotsch","year":"2006","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.mayocp.2012.02.022_bib83","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuroscience.2004.12.033","article-title":"Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm","volume":"133","author":"Pan","year":"2005","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.mayocp.2012.02.022_bib84","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1297-319X(02)00435-9","article-title":"Opioid rotation in the treatment of joint pain","volume":"69","author":"Grilo","year":"2002","journal-title":"Joint Bone Spine"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib85","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ctrv.2006.03.001","article-title":"Opioid switching: a systematic and critical review","volume":"32","author":"Mercadante","year":"2006","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.mayocp.2012.02.022_bib86","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1213\/00000539-200004000-00029","article-title":"Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review","volume":"90","author":"Quang-Cantagrel","year":"2000","journal-title":"Anesth Analg"},{"issue":"12","key":"10.1016\/j.mayocp.2012.02.022_bib87","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/11530800-000000000-00000","volume":"29","author":"Stauffer","year":"2009","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.mayocp.2012.02.022_bib88","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jpainsymman.2010.05.004","article-title":"Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain","volume":"40","author":"Webster","year":"2010","journal-title":"J Pain Symptom Manage"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612004818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612004818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:47:30Z","timestamp":1706003250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619612004818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0025619612004818"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2012.02.022","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to Reduce the Tampering and Subsequent Abuse of Long-acting Opioids: Potential Risks and Benefits of Formulations With Physical or Pharmacologic Deterrents to Tampering","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2012.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}